# To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

> **NCT00790153** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 12 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Insulin
- **DRUG:** AZD1656

## Key facts

- **NCT ID:** NCT00790153
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** —
- **Final completion:** 2009-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2009-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790153, "To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00790153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*